What is the target of rubicatin targeted drugs?

Lurbinectedin (Lurbinectedin) is a targeted drug. Its special feature is that it does not directly target a specific target, but exerts anti-cancer effects by affecting the transcription process of DNA. Specifically, rubicatin is an alkylating drug that can bind to guanine residues in the minor groove of DNA to form an adduct and cause the DNA helix to bend toward the major groove. The formation of this adduct triggers a cascade of events that may affect the subsequent activity of DNA-binding proteins (including certain transcription factors) and DNA repair pathways, leading to cell cycle disorders and ultimately cell death.

Rubicatin received accelerated approval from the U.S. Food and Drug Administration (FDA) in June 2020 for the treatment of adult patients with metastatic small cell lung cancer (SCLC) whose disease has progressed after platinum-based chemotherapy. The approval was based on overall response rate (ORR) and duration of response (DOR) data. In clinical trials, rubicatin has demonstrated significant efficacy against small cell lung cancer, particularly in second-line treatment after failure of platinum-based chemotherapy.

It is worth noting that rubicatin not only affects cancer cells, but may also affect the transcription process in normal body cells. Therefore, caution is required during use and dosage adjustments should be made based on the patient's specific condition. In addition, although rubicatin provides a new treatment option for patients with small cell lung cancer, it is not suitable for all patients, and its efficacy and safety need to be further verified in more clinical trials.

In general, the "target" of Rubicatin is not a single protein or molecule in the traditional sense, but plays an anti-cancer effect by affecting the DNA transcription process. This unique mechanism makes rubicatin an emerging treatment option for small cell lung cancer, especially after other treatment options have failed. However, its use still requires caution and needs to be tailored and optimized to the patient's specific circumstances.